Noul Co., Ltd. (CEO Chan-Yang Lim, hereinafter referred to as 'Noul') announced on the 7th that it has signed a memorandum of understanding (MOU) with Seegene Brazil for the local introduction of its AI-based cervical cancer solution 'miLabTM CER'.
Through this MOU, the two companies will continue to collaborate in various areas with the goal of signing a non-exclusive distribution agreement for Noul's product portfolio, including Noul's AI-based cervical cancer solution miLab CER, within Seegene's Brazil sales territory.
Noul CEO Chan-Yang Lim said, “With this MOU, we expect to achieve multifaceted cooperation for the distribution of Noul’s AI-based cervical cancer diagnostic platform in Brazil by combining Seegene’s expertise in molecular diagnostics with its distribution network in Brazil.” He added, “As with our recent contract with Nihon Kohden, a global medical device manufacturer, and this MOU with Seegene Brazil, we will actively pursue collaborations with global medical device manufacturers that are interested in Noul’s innovative AI diagnostic technology.”
Meanwhile, Noul's miLab CER, a compact, all-in-one solution for AI-based cervical cancer diagnosis, received official recommendation for use in the 2024 WHO-UNITAID report.
- See more related articles
You must be logged in to post a comment.